Aeglea Biotherapeutics Inc. (AGLE) Raised to Hold at Zacks Investment Research
Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Aeglea Biotherapeutics (NASDAQ:AGLE) traded up 6.15% during midday trading on Tuesday, hitting $6.90. 9,785 shares of the stock traded hands. The stock’s 50-day moving average price is $6.64 and its 200-day moving average price is $6.59. Aeglea Biotherapeutics has a 52 week low of $3.89 and a 52 week high of $12.75. The stock’s market capitalization is $92.54 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/aeglea-biotherapeutics-inc-agle-raised-to-hold-at-zacks-investment-research.html
Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities research analysts expect that Aeglea Biotherapeutics will post ($4.77) EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Ghost Tree Capital LLC bought a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $243,000. Perceptive Advisors LLC bought a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $515,000. Finally, VHCP Management II LLC bought a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $1,527,000. 40.71% of the stock is owned by institutional investors and hedge funds.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.